Broad-spectrum β-lactamases in Gram-negative bacteria;Bredspektrede betalaktamaser hos gramnegative stavbakterier

Tidsskrift for den Norske Laegeforening

Volumn 128, Issue 23, 2008, Pages 2741-2745

  Sundsfjord, Arnfinn ^a,b   Simonsen, Gunnar Skov ^a,c,d   Haldorsen, Bjørg ^b   Lundblad, Eirik Wasmuth ^b   Samuelsen, Ørjan ^b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b Kompetansesenter for Påvisning av Antibiotikaresistens   (Norway)

^c Avdeling for Mikrobiologi og Smittevern   (Norway)

^d Divisjon for Smittevern   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58149252141     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. NORM/NORM-VET 2006. Usage of antimicrobial agents and occurrence of antimicrobial resistance in Norway. www.vetinst.no/nor/Forskning/Rapporter/Norm- Norm-Vet-rapporten (28.8.2008).
2. Walsh TR, Toleman MA, Poirel L et al. Metallobetalactamases: the quiet before the storm? Clin Microbiol Rev 2005; 18: 306-25.
3. Canton R, Coque TM. The CTX-M betalactamase pandemic. Curr Opin Microbiol 2006; 9: 466-75.
4. Livermore D, Woodford N. The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol 2006; 14: 2974-6.
5. Queenan Am, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 2007; 20: 440-58.
6. Zavascki AP, Goldani LZ, Nation RL. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 2007; 60: 1206-15.
7. Samuelsen Ø, Buarø L, Giske CG et al. Evaluation of phenotypic tests for the detection of metallobeta-lactamase-producing Pseudomonas aeruginosa in a low prevalence country. J Antimicrob Chemother 2008: 61: 827-30.
8. th European Congress of Clinical Microbiology and Infectious Diseases. München: ECCMID, 2007.
9. th European Congress of Clinical Microbiology and Infectious Diseases. Barcelona: ECCMID, 2008.
10. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933-51.
11. Livermore D. Beta-lactamase mediated resistance and opportunities for its control. J Antimicrobial Chemother 1998; 41 (suppl D): 25-41.
12. Lahey clinic. www.lahey.org/studies (28.8.2008).
13. OXY,OKP, LEN beta-lactamase protein variation home page. www.pasteur.fr/recherche/genopole/PF8/betalact_en.html (28.8.2008).
14. Livermore D. Defining an extended-spectrum betalactamase. Clin Microbiol Infect 2008; 14 (suppl 1): 3-10.
15. Tofteland S, Haldorsen B, Dahl KH et al. Effects of phenotype and genotype on methods for detection of extended-spectrum-beta-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway. J Clin Microbiol 2007; 45: 199-205.
16. Nyberg SD, Osterblad M, Hakanen J et al. Detection and molecular genetics of extended-spectrum beta-lactamases among cefuroxime-resistant Escherichia coli and Klebsiella spp. isolates from Finland, 2002-2004. Scand J Infect Dis 2007; 39: 417-24.
17. Fang H, Ataker F, Hedin G et al. Molecular epidemiology of extended-spectrum beta-lactamases among Escherichia coli isolates collected in a Swedish Hospital and its associated health care facilities from 2001 to 2006. J Clin Microbiol 2008; 46: 707-12.
18. Oteo J, Navarro C, Cercenado E et al. Spread of Escherichia coli strains with high-level cefotaxime and ceftazidime resistance between the community, long-term care facilities, and hospital institutions. J Clin Microbiol 2006; 44: 2359-66.
19. Livermore DM, Canton R, Gniadkowski M et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007; 59: 165-74.
20. Nicolle LE, Mulvey MR. Successful treatment of CTX-M ESBL producing Escherichia coli relapsing pyelonephritis with long term pivmecillinam. Scand J Infect Dis 2007; 39: 748-9.
21. Naseer U, Natås OB, Haldorsen BC et al. Nosocomial outbreak of CTX-M-15-producing E. coli in Norway. APMIS 2007; 115: 120-6.
22. Søderholm T, Struwe J. Extended spectrum beta-lactamase-producing Enterobacteriaceae: the first six months of notifications according to the Swedish communicable disease act. Eurosurveillance 2007; 12: E071018.1
23. Schwaber MJ, Navon-Venezia S, Kaye KS et al. Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2006; 50: 1257-62.
24. Coque TM, Novaia A, Carattoli A et al. Dissemination of clonally related Escherichia coli strains expressing extended-spectrum beta-lactamase CTX-M-15. Emerg Infect Dis 2008; 14: 195-200.
25. Valverde A, Coque TM, Sanchez-Moreno MP et al. Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol 2004; 42: 4769-75.
26. Warren RE, Harvey G, Carr R et al. Control of infections due to extended-spectrum beta-lactamase-producing organisms in hospitals and the community. Clin Microbiol Infect 2008; 14 (suppl 1): 124-33.
27. Jacoby GA, Walsh KE, Walker VJ. Identification of extended-spectrum, AmpC, and carbapenemhydrolyzing beta-lactamases in Escherichia coli and Klebsiella pneumoniae by disk tests. J Clin Microbiol 2006; 44: 1971-6.
28. th European Congress of Clinical Microbiology and Infectious Diseases. München: ECCMID, 2007.
29. Philippon A, Arlet G, Jacoby GA. Plasmid-determined AmpC-type beta-lactamases. Antimicrob Agents Chemother 2002; 46: 1-11.
30. Haldorsen B, Aasnæs B, Dahl KH et al. the AmpC phenotype in Norwegian clinical isolates of Escherichia coli is associated with an acquired ISEcp1-like ampC element or hyperproduction of the endogenous AmpC. J Antimicrob Chemother 2008; 62: 694-702.
31. Li Y, Li Q, Du Y et al. Prevalence of plasmid-mediated AmpC beta-lactamasese in a Chinese University Hospital from 2003 to 2005: first report of CMY-2 AmpC beta-lactamase resistance in China. J Clin Microbiol 2008; 46: 1317-21.
32. Watanabe M, Iyobe S, Inoue M et al. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991; 35: 147-51.
33. The European Antimicrobial Resistance Surveillance System. EARSS annual report 2006. www.rivm.nl/earss (28.8.2008).
34. Perez F, Hujer AM, Hujer KM et al. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51: 3471-84.
35. Fournier PE, Vallenet D, Barbe V et al. Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet 2006; 2: e7.
36. Coelho JM, Turton JF, Kaufmann ME et al. Occurrence of carbapenem-resistant Acinetobacter baumannii clones at multiple hospitals in London and Southeast England. J Clin Microbiol 2006; 44: 3623-7.
37. Onarheim H, Høivik T, Harthug S et al. Utbrudd av multiresistent Acinetobacter baumannii infeksjon. Tidsskr Nor Lægeforen 2000; 120: 1028-33.
38. Yigit H, Queenan AM, Anderson GJ et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001; 45: 1151-61.
39. Vourli S, Giakkoupi P, Polemis MZ et al. Study of the molecular epidemiology of metallo-beta-lactamase-producing Klebsiella pneumoniae in Greece. Abstract 18th European Congress of Clinical Microbiology and Infectious Diseases. Barcelona: ECCMID, 2008.
40. Universitetssykehuset Nord-Norge. Antibiotika og antibiotikaresistens. www.antibiotikaresistens.no (28.8.2008).